Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BMS ‘Slow-Rolled’ Approval of Liso-Cel, Investors Claim, Citing Timeline Of Other CAR-T Therapies

Executive Summary

Two complaints allege BMS deliberately delayed approval of non-Hodgkins lymphoma treatment to avoid $6.4bn contingency payment. Former FDA reviewer is expert for plaintiffs in securities class action arguing that similar cell therapies Yescarta and Kymriah were approved twice as fast.

You may also be interested in...



Breyanzi Is Third To Market, But BMS’s First CAR-T Therapy Priced Above Competitors

Breyanzi’s list price is $410,300. The CD19-targeting CAR-T therapy previously known as liso-cel has a lot of ground to make up following competitors Yescarta and Kymriah. 

It Was Inevitable: FDA Inspection Delay Postpones BMS’s Liso-Cel Approval

Bristol Myers Squibb confirmed that approval for lisocabtagene maraleucel (liso-cel) will be delayed by the US FDA’s COVID-19-related restrictions on travel for manufacturing facility inspectors.

Top US FDA Official Says New 'Playbook' Needed For CMC Reviews Of Gene Therapy Products

CBER director says lack of a clear regulatory structure is holding back the development and acceleration of gene therapy products, while industry says regulations should be flexible to keep up with changing technology for these products.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145773

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel